MSA Clinical Features and Diagnosis

MSA Clinical Features and Diagnosis

Multiple System Atrophy (MSA) presents with a complex clinical phenotype that combines parkinsonism, cerebellar dysfunction, and autonomic failure in varying combinations. This page details the clinical presentation, diagnostic criteria, disease variants, and progression patterns that characterize this devastating disorder.

Clinical Phenotypes

MSA with Parkinsonian Features (MSA-P)

The Parkinsonian variant accounts for approximately 70% of MSA cases:

Core Motor Features:

• Bradykinesia: Progressive slowing of voluntary movements
• Rigidity: Cogwheel or lead-pipe rigidity, often symmetric
• Postural instability: Frequent falls, typically within 3 years of onset
• Resting tremor: Less prominent than in Parkinson's disease (10-20%)

Distinguishing from Parkinson's Disease:

• Rapid progression (median time to falls: 4-5 years)
• Poor levodopa response (<30% achieve sustained benefit)
• Early autonomic failure (within 1-2 years of motor onset)
• Symmetric onset (vs. asymmetric in PD)

MSA with Cerebellar Features (MSA-C)

The cerebellar variant accounts for approximately 30% of cases:

Core Cerebellar Features:

• Gait ataxia: Wide-based, unsteady gait with frequent falls
• Limb dysmetria: Impaired coordination in arm/leg movements
• Scanning speech: Slow, irregular speech with inappropriate pauses
• Nystagmus: Gaze-evoked horizontal nystagmus, often vertical

...

MSA Clinical Features and Diagnosis

Multiple System Atrophy (MSA) presents with a complex clinical phenotype that combines parkinsonism, cerebellar dysfunction, and autonomic failure in varying combinations. This page details the clinical presentation, diagnostic criteria, disease variants, and progression patterns that characterize this devastating disorder.

Clinical Phenotypes

MSA with Parkinsonian Features (MSA-P)

The Parkinsonian variant accounts for approximately 70% of MSA cases:

Core Motor Features:

• Bradykinesia: Progressive slowing of voluntary movements
• Rigidity: Cogwheel or lead-pipe rigidity, often symmetric
• Postural instability: Frequent falls, typically within 3 years of onset
• Resting tremor: Less prominent than in Parkinson's disease (10-20%)

Distinguishing from Parkinson's Disease:

• Rapid progression (median time to falls: 4-5 years)
• Poor levodopa response (<30% achieve sustained benefit)
• Early autonomic failure (within 1-2 years of motor onset)
• Symmetric onset (vs. asymmetric in PD)

MSA with Cerebellar Features (MSA-C)

The cerebellar variant accounts for approximately 30% of cases:

Core Cerebellar Features:

• Gait ataxia: Wide-based, unsteady gait with frequent falls
• Limb dysmetria: Impaired coordination in arm/leg movements
• Scanning speech: Slow, irregular speech with inappropriate pauses
• Nystagmus: Gaze-evoked horizontal nystagmus, often vertical

Brainstem Involvement:

• Dysphagia (swallowing difficulties)
• Dysarthria (speech impairment)
• Oculomotor abnormalities

Autonomic Dysfunction

Autonomic failure is a mandatory feature for probable MSA diagnosis:

Cardiovascular Autonomy

Orthostatic Hypotension:

• Sustained drop ≥20 mmHg systolic or ≥10 mmHg diastolic within 3 minutes of standing
• Occurs in >70% of patients at diagnosis
• Often accompanied by supine hypertension

Heart Rate Abnormalities:

• Reduced heart rate variability
• Impaired baroreflex sensitivity
• Cardiac sympathetic denervation (MIBG scintigraphy shows absence of uptake)

Urinary Dysfunction

Early Features:

• Urinary urgency and frequency
• Nocturia (multiple nighttime awakenings)

Established Disease:

• Urinary incontinence (often urge-type)
• Incomplete bladder emptying
• Recurrent urinary tract infections

Other Autonomic Features

• Erectile dysfunction: Often precedes motor symptoms in men
• Gastrointestinal dysmotility: Early satiety, nausea, constipation
• Anhidrosis: Loss of sweating, particularly on face and trunk

Sleep Disorders

REM Sleep Behavior Disorder (RBD)

• Present in up to 80% of MSA patients
• Often precedes motor symptoms by years
• Characterized by loss of REM atonia, leading to dream enactment
• Polysomnography shows elevated REM sleep without atonia

Sleep-Disordered Breathing

• Obstructive sleep apnea: Present in ~50%
• Central sleep apnea: Particularly in MSA-C variant
• Nocturnal stridor: Rare but serious, requires monitoring

Cognitive and Psychiatric Features

Cognitive Profile

• Executive dysfunction: Impaired planning, set-shifting, working memory
• Processing speed: Significant slowing of information processing
• Memory: Relative preservation compared to cortical dementias
• Visuospatial: Mild impairment in later stages
• Dementia: Present in 10-20%, typically subcortical type

Psychiatric Comorbidities

• Depression: Up to 40% prevalence
• Anxiety: Common, often co-occurring with depression
• Apathy: Present in 20-30%
• Psychosis: Less common than in Lewy body dementia

Diagnostic Criteria

Second Consensus Criteria (2008)

Probable MSA:

• Sporadic, adult-onset disease
• Autonomic failure (orthostatic hypotension + urinary dysfunction)
• Plus parkinsonism (bradykinesia + rigidity) OR cerebellar syndrome (gait ataxia + limb ataxia)
• Poor response to levodopa

Possible MSA:

• Autonomic failure + one of: parkinsonism or cerebellar syndrome
• OR parkinsonism/cerebellar syndrome + one of: MRI abnormalities or laboratory findings

Supportive Features

Imaging Findings:

• MRI: Putaminal atrophy, pontine atrophy, middle cerebellar peduncle hyperintensity
• PET/SPECT: Reduced dopamine transporter binding, regional hypometabolism

Laboratory Findings:

• Urinary dysfunction (detrusor overactivity)
• Cold extremities with dependent edema

Differential Diagnosis

| Feature | MSA | PSP | CBD | PD |
|---------|-----|-----|-----|-----|
| Autonomic failure | Early, prominent | Late, mild | Late, mild | Late, mild |
| Levodopa response | Poor | Poor | Poor | Good |
| Symmetry | Symmetric | Symmetric | Asymmetric | Asymmetric |
| Disease progression | Rapid | Moderate | Moderate | Slow |
| Eye movements | Rare | Vertical supranuclear gaze palsy | Variable | Normal |

Disease Progression

Early Stage (0-3 years)

• Insidious onset of motor symptoms
• Early autonomic dysfunction
• Often misdiagnosed as PD
• Functional independence maintained

Mid Stage (3-6 years)

• Progressive motor disability
• Frequent falls
• Need for assistive devices
• Autonomic symptoms become severe

Late Stage (>6 years)

• Wheelchair dependence
• Severe dysphagia
• Nursing home placement common
• Median survival: 6-9 years from onset

Clinical Management

Symptomatic Treatment

• Parkinsonism: Trial of levodopa, modest benefit in ~30%
• Orthostatic hypotension: Midodrine, fludrocortisone, compression stockings
• Urinary dysfunction: Oxybutynin, tamsulosin
• Depression: SSRIs (cautious due to orthostatic hypotension)

Supportive Care

• Physical therapy for gait and balance
• Speech therapy for dysarthria and dysphagia
• Occupational therapy for activities of daily living
• Regular monitoring for sleep-disordered breathing

Conclusion

MSA presents with a distinctive combination of autonomic failure, parkinsonism, and/or cerebellar dysfunction that distinguishes it from other movement disorders. Early recognition of autonomic symptoms and understanding of the clinical variants is critical for accurate diagnosis and appropriate management. The rapid progression and poor treatment response underscore the need for disease-modifying therapies.

References

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

Unknown (n.d.)

[Gilman et al., Second consensus statement on the diagnosis of MSA (2008)](https://pubmed.ncbi.nlm.nih.gov/18617760/)

[Kaufmann et al., Natural history of autonomic dysfunction in MSA (2022)](https://pubmed.ncbi.nlm.nih.gov/35820789/)

[Wenning et al., Multiple system atrophy: features and prognosis (2013)](https://doi.org/10.1016/S1474-4422(13)70059-1)

[Stamelou et al., Clinical features of MSA (2012)](https://doi.org/10.1007/s11910-012-0280-7)

[Cohen et al., MRI in multiple system atrophy (2022)](https://doi.org/10.1038/s41582-022-00656-4)

[Fede et al., Autonomic dysfunction in atypical parkinsonism (2020)](https://doi.org/10.1007/s10286-020-00673-4)